# Targeting EBV-associated lymphomas

> **NIH NIH U01** · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $645,012

## Abstract

ABSTRACT
Epstein-Barr Virus (EBV) is the etiological agent of several hematopoietic malignancies including multiple types
of non-Hodgkin lymphoma (NHL). These EBV-positive NHL subtypes are comprised of post-transplant
lymphoproliferative disease (PTLD), diffuse large B cell lymphomas (DLBCL), T cell lymphomas, Natural killer
(NK)/T cell lymphoma (NKTL), and Burkitt's lymphoma (BL). Our studies have found that FAM72A is highly
expressed in EBV-positive lymphomas and contributes to EBV-mediated lymphomagenesis, which gives rise to
EBV-positive NHL. In response to PAR-21-348, we propose to address how EBV’s upregulation of FAM72A
contributes to the development of EBV-driven NHL.

## Key facts

- **NIH application ID:** 11001649
- **Project number:** 1U01CA294800-01
- **Recipient organization:** UNIV OF NORTH CAROLINA CHAPEL HILL
- **Principal Investigator:** BLOSSOM A DAMANIA
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $645,012
- **Award type:** 1
- **Project period:** 2024-09-10 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11001649

## Citation

> US National Institutes of Health, RePORTER application 11001649, Targeting EBV-associated lymphomas (1U01CA294800-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/11001649. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*